Evidence map›Paper›PMID 36104200›Full record

ReviewInternal medicine (Tokyo, Japan)2023

Severe Enteritis after Cyclophosphamide Administration in a Patient with Microscopic Polyangiitis: A Case Report and Literature Review.

Shuhei Yoshida, Jumpei Temmoku, Tomoyuki Asano, Tsuyoshi Iwasaki, Haruki Matsumoto, Yuya Fujita, Makiko Yashiro-Furuya, Naoki Matsuoka, Naohiko Gunji, Shuzo Sato and 3 more

Open access · diamondAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Oligosaccharides from the seeds ofFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shuhei YoshidaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Jumpei TemmokuDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Tomoyuki AsanoDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Tsuyoshi IwasakiDepartment of Nephrology and Hypertension, Fukushima Medical University School of Medicine, Japan.
Haruki MatsumotoDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Yuya FujitaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Makiko Yashiro-FuruyaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Naoki MatsuokaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Naohiko GunjiDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
Shuzo SatoDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Hiroshi WatanabeDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
Kiyoshi MigitaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe enteritis is a rare side effect of cyclophosphamide (CPA) therapy, and only two cases have been reported to date. We herein report a 60-year-old man who developed severe enteritis after intravenous CPA administration for microscopic polyangiitis. He was successfully treated by discontinuation of CPA administration and long-term intensive supportive care. A diagnosis of CPA-associated enteritis was made based on the clinical course and imaging and pathological findings. This review of three cases of CPA-related enteritis, including our case, suggests that prompt CPA discontinuation and intensive systemic management are necessary when patients have gastrointestinal symptoms after CPA administration.

Indexed as

EnteritisMicroscopic PolyangiitisAdministration, IntravenousCyclophosphamideHumansInfusions, IntravenousMaleMiddle AgedCyclophosphamidecyclophosphamideenteritismicroscopic polyangiitis

Identifiers

PMID36104200
PMCPMC10208791
OpenAlexW4295903641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.